Grant: Idea to Innovation
University of Toronto
$15,000.00
Market Assessment of a novel magnetic resonance imaging platform for long-term In-vivo cell tracking
EF 2021-22
Résumé
This proposal seeks to fund a market assessment of a novel magnetic resonance imaging (MRI) platform for sensitive and long-term tracking of therapeutic cells deep in the body. Therapeutic cells, such as stem cells, are used to repair damaged tissue and grow new ones. Currently, stem cells are used to treat patients with leukemia or other blood disorders. Many other tissue targets are under intense development worldwide but have not advanced into the clinic, including stem cell therapy to treat the brain and nervous system, heart, liver, kidneys, and skeletal muscle. While each organ has its own set of specific challenges and some are decades away from benefiting patients, a common hurdle is the current gap in our ability to monitor cells in the body. In preclinical animal studies, it is extremely difficult to optimize the ingredients for successful therapy without a way to look deep into the body and see if transplanted cells stay, grow, and contribute to new function. Eventually, in human stem cell transplant patients, it would be extremely valuable if we had a way to monitor the progress and success of therapy.The Cheng Lab has discovered a new mechanism for creating bright signal from cells, even human stem cells. This platform is based on MRI and offers the unique combination of high-sensitivity, long-term cell tracking, deep-tissue imaging, and non-invasiveness. Existing cell tracking technologies offer either high sensitivity or long-term tracking, not both, and may involve ionizing radiation. Briefly, our technology turns on the bright signal from stem cells at any time post-transplantation. Signal is generated only in cells that remain alive. In this way, one can determine and localize cell survival and their integration in new tissue. The group has filed a provisional patent and is working towards a PCT patent. The market assessment is the first step towards securing additional I2I funding that will be key in developing this cell tracking MRI platform into a research tool for a vast expanse of preclinical research.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
561439-2021
Name nom
Cheng, Hai-Ling
Department département
Biomedical Engineering, Institute of (BME)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2021
Award amount
15000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:1
Partie
1
Nb partie
1
Application title
Market Assessment of a novel magnetic resonance imaging platform for long-term In-vivo cell tracking
Keyword
NSERC
Application summary
This proposal seeks to fund a market assessment of a novel magnetic resonance imaging (MRI) platform for sensitive and long-term tracking of therapeutic cells deep in the body. Therapeutic cells, such as stem cells, are used to repair damaged tissue and grow new ones. Currently, stem cells are used to treat patients with leukemia or other blood disorders. Many other tissue targets are under intense development worldwide but have not advanced into the clinic, including stem cell therapy to treat the brain and nervous system, heart, liver, kidneys, and skeletal muscle. While each organ has its own set of specific challenges and some are decades away from benefiting patients, a common hurdle is the current gap in our ability to monitor cells in the body. In preclinical animal studies, it is extremely difficult to optimize the ingredients for successful therapy without a way to look deep into the body and see if transplanted cells stay, grow, and contribute to new function. Eventually, in human stem cell transplant patients, it would be extremely valuable if we had a way to monitor the progress and success of therapy.The Cheng Lab has discovered a new mechanism for creating bright signal from cells, even human stem cells. This platform is based on MRI and offers the unique combination of high-sensitivity, long-term cell tracking, deep-tissue imaging, and non-invasiveness. Existing cell tracking technologies offer either high sensitivity or long-term tracking, not both, and may involve ionizing radiation. Briefly, our technology turns on the bright signal from stem cells at any time post-transplantation. Signal is generated only in cells that remain alive. In this way, one can determine and localize cell survival and their integration in new tissue. The group has filed a provisional patent and is working towards a PCT patent. The market assessment is the first step towards securing additional I2I funding that will be key in developing this cell tracking MRI platform into a research tool for a vast expanse of preclinical research.